ReviewFrontiers in immunology2022

Focusing on NK cells and ADCC: A promising immunotherapy approach in targeted therapy for HER2-positive breast cancer.

Feifei Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.